RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of DirectorsGlobeNewsWire • 11/09/21
Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/08/21
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease SummitGlobeNewsWire • 10/18/21
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology CongressGlobeNewsWire • 09/30/21
Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/05/21
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/18/21
RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?Zacks Investment Research • 06/15/21
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic DermatitisGlobeNewsWire • 06/14/21
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic DermatitisGlobeNewsWire • 06/13/21
Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock OptionsZacks Investment Research • 05/19/21